Log in to save to my catalogue

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c0127f48b27847648095dd1f0a306360

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells

About this item

Full title

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells

Publisher

London: Nature Publishing Group UK

Journal title

Scientific reports, 2022-05, Vol.12 (1), p.8007-8007, Article 8007

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Lenvatinib is approved as a first-line treatment for unresectable HCC. The therapeutic duration of lenvatinib is limited by resistance, but the underlying mechanism is unclear. To establish lenvatinib-resistant cells, Hep3B cells were initially treated with 3 µM le...

Alternative Titles

Full title

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_c0127f48b27847648095dd1f0a306360

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c0127f48b27847648095dd1f0a306360

Other Identifiers

ISSN

2045-2322

E-ISSN

2045-2322

DOI

10.1038/s41598-022-12076-w

How to access this item